189 related articles for article (PubMed ID: 18008346)
1. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
Filho AL; Baltazar F; Bedrossian C; Michael C; Schmitt FC
Diagn Cytopathol; 2007 Dec; 35(12):786-91. PubMed ID: 18008346
[TBL] [Abstract][Full Text] [Related]
2. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma.
Niki T; Iba S; Yamada T; Matsuno Y; Enholm B; Hirohashi S
J Pathol; 2001 Apr; 193(4):450-7. PubMed ID: 11276003
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
4. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
5. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
6. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors.
Partanen TA; Alitalo K; Miettinen M
Cancer; 1999 Dec; 86(11):2406-12. PubMed ID: 10590384
[TBL] [Abstract][Full Text] [Related]
7. Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis.
Mogi A; Nabeshima K; Hamasaki M; Uesugi N; Tamura K; Iwasaki A; Shirakusa T; Iwasaki H
Pathol Int; 2009 Dec; 59(12):874-9. PubMed ID: 20021613
[TBL] [Abstract][Full Text] [Related]
8. Retiform hemangioendotheliomas usually do not express D2-40 and VEGFR-3.
Parsons A; Sheehan DJ; Sangueza OP
Am J Dermatopathol; 2008 Feb; 30(1):31-3. PubMed ID: 18212541
[TBL] [Abstract][Full Text] [Related]
9. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor in malignant mesothelioma.
Aoe K; Hiraki A; Tanaka T; Gemba K; Taguchi K; Murakami T; Sueoka N; Kamei T; Ueoka H; Sugi K; Yoshino T; Kishimoto T
Anticancer Res; 2006; 26(6C):4833-6. PubMed ID: 17214348
[TBL] [Abstract][Full Text] [Related]
12. c-Kit is not expressed in malignant mesothelioma.
Horvai AE; Li L; Xu Z; Kramer MJ; Jablons DM; Treseler PA
Mod Pathol; 2003 Aug; 16(8):818-22. PubMed ID: 12920227
[TBL] [Abstract][Full Text] [Related]
13. Podoplanin as a marker for mesothelioma.
Kimura N; Kimura I
Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
[TBL] [Abstract][Full Text] [Related]
14. Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
Kahlos K; Pääkkö P; Kurttila E; Soini Y; Kinnula VL
Br J Cancer; 2000 Mar; 82(5):1022-9. PubMed ID: 10737384
[TBL] [Abstract][Full Text] [Related]
15. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma.
Clarijs R; Schalkwijk L; Hofmann UB; Ruiter DJ; de Waal RM
Cancer Res; 2002 Dec; 62(23):7059-65. PubMed ID: 12460927
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
O'Kane SL; Cawkwell L; Campbell A; Lind MJ
Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
Onofri C; Losa M; Uhl E; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
[TBL] [Abstract][Full Text] [Related]
19. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
20. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
